Here’s the latest on Bombay blood group (hh phenotype) based on recent public reporting.
- What it is: Bombay blood group is an extremely rare hh phenotype lacking the H antigen, which makes it incompatible with all standard blood types. It was first identified in Mumbai in 1952 and remains one of the rarest blood groups worldwide. This foundational fact is repeatedly highlighted in recent explainers and news coverage.[1][3]
- Recent developments: There have been high-profile reports of a first-of-its-kind kidney transplant in Mumbai for a patient with Bombay blood group, underscoring ongoing medical advances and the unique transfusion/transplantation needs of these patients.[2][1]
- Practical implications: Because Bombay blood group donations must come from matching hh donors, donors with this rare type are organized through specialized networks, and cross-matching remains more complex than for common blood groups; storage and supply challenges are frequently discussed in health news and NGO channels.[6][9]
- Public awareness context: You’ll see discussions across Indian health news outlets and educational channels explaining how Bombay blood group can be confused with type O in initial testing, but true compatibility requires hh matching due to the anti-H antibodies that can cause reactions.[3][8]
Illustrative note
- A representative recent narrative: a 30-year-old woman with Bombay blood group underwent a kidney transplant in Mumbai, illustrating the real-world challenges and life-saving potential associated with this blood type.[2]
If you’d like, I can pull regional updates from South Asia or North America, or summarize what hospitals are doing to maintain donor networks for hh-compatible transfusions. I can also provide a brief patient-facing explainer or a glossary of key terms (hh phenotype, anti-H antibodies, cross-mmatching) with simple definitions.
Citations:
- Bombay blood group overview and hh phenotype details[1][3]
- Recent kidney transplant case in Mumbai involving Bombay blood group[2]
- Storage and donor-network considerations in rare blood groups[9][6]